13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802630
Total reported value
$2.9B
$2.9B
92 檔
8.7%
At the close of Q2 2024, Soleus Capital Management, L.P. disclosed equity holdings valued at approximately $2.9B, spread across 92 reported holdings.
During Q2 2024, Soleus Capital Management, L.P.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 5.72% | +0.12% | +15.06% | |
| 2 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 5.34% | -0.12% | +115.35% | |
| 3 | UTHR | United Therapeutics CORP | Stock-Healthcare | 3.97% | -0.29% | -45.52% | |
| 4 | NRIX | Nurix Therapeutics Inc | Stock-Other | 3.78% | +0.63% | +84.39% | |
| 5 | FOCL | Edap Tms SA -adr | Stock-Other | 3.50% | +0.20% | +0.92% | |
| 6 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.97% | — | — | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.93% | — | +17.49% | |
| 8 | SU6 | Surmodics Inc | Stock-Other | 2.90% | — | -2.38% | |
| 9 | ORGO | Organogenesis Holdings Inc | Stock-Other | 2.84% | -0.12% | +20.32% | |
| 10 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.55% | -0.01% | EXIT | |
| 11 | IDYA | Ideaya Biosciences Inc | Stock-Other | 2.15% | — | +30.09% | |
| 12 | AXGN | Axogen Inc | Stock-Other | 2.11% | -0.82% | +6.44% | |
| 13 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 2.04% | -0.03% | +49.82% | |
| 14 | ✓ | Merus N V | Stock-Other | 1.96% | — | +92.42% | |
| 15 | PEN | Penumbra Inc | Stock-Healthcare | 1.96% | — | +44.05% | |
| 16 | EPIEUR | Essa Pharma Inc | Stock-Other | 1.95% | — | +17.30% | |
| 17 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.94% | -2.26% | +1330.22% | |
| 18 | CELC | Celcuity Inc | Stock-Other | 1.75% | +0.20% | -30.04% | |
| 19 | NARIUSD | Inari Medical Inc | Stock-Other | 1.73% | — | +47.43% | |
| 20 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.73% | — | -7.02% | |
| 21 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.65% | +0.13% | +64.78% | |
| 22 | CSTL | Castle Biosciences Inc | Stock-Other | 1.64% | — | +17.67% | |
| 23 | NPCE | Neuropace Inc | Stock-Other | 1.62% | +0.03% | — | |
| 24 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.59% | -0.08% | — | |
| 25 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.54% | -1.42% | — | |
| 26 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.50% | -0.40% | +123.98% | |
| 27 | HUM | Humana Inc | Stock-Healthcare | 1.46% | — | -38.40% | |
| 28 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.41% | — | +30.01% | |
| 29 | TMCI | Treace Medical Concepts Inc | Stock-Other | 1.39% | — | +75.80% | |
| 30 | PCVX | Vaxcyte Inc | Stock-Other | 1.23% | -0.91% | EXIT | |
| 31 | TXG | 10x Genomics Inc-class A | Stock-Other | 1.23% | — | — | |
| 32 | CGON | Cg Oncology Inc | Stock-Other | 1.18% | -0.04% | +94.88% | |
| 33 | NUVL | Nuvalent Inc-a | Stock-Other | 1.15% | — | +32.87% | |
| 34 | EOLS | Evolus Inc | Stock-Other | 1.10% | -0.17% | +620.00% | |
| 35 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.91% | — | +37.72% | |
| 36 | ALEC | Alector Inc | Stock-Other | 0.90% | — | — | |
| 37 | KROS | Keros Therapeutics Inc | Stock-Other | 0.89% | — | -19.01% | |
| 38 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.84% | — | -83.18% | |
| 39 | ACLXGBX | Arcellx Inc | Stock-Other | 0.83% | — | +13.83% | |
| 40 | ✓ | Biodesix Inc | Stock-Other | 0.82% | — | — | |
| 41 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.79% | +0.38% | -22.24% | |
| 42 | KIDS | Orthopediatrics CORP | Stock-Other | 0.78% | +0.08% | — | |
| 43 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 0.76% | +2.48% | — | |
| 44 | BHC | Bausch Health Cos Inc | Stock-Healthcare | 0.74% | — | +80.00% | |
| 45 | VTLUSD | Immunic Inc | Stock-Other | 0.71% | -0.20% | EXIT | |
| 46 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 0.69% | — | +13.49% | |
| 47 | ✓ | Engene Holdings Inc | Stock-Other | 0.67% | — | — | |
| 48 | PHVS | Pharvaris N.V. | Stock-Other | 0.66% | +0.07% | -0.61% | |
| 49 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 0.63% | — | — | |
| 50 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.63% | — | — |
According to official SEC Form 13F filings, Soleus Capital Management, L.P. reported a total U.S. public equity portfolio value of $2.9B across 92 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TGTX, IOVA, UTHR) accounted for 8.7% of total reported equity market value during Q2 2024.
During Q2 2024, Soleus Capital Management, L.P.'s top holdings by market value included TGTX (5.7%)、IOVA (5.3%)、UTHR (4.0%). The largest single position, TGTX, represented 5.7% of total portfolio value.
In Q2 2024, Soleus Capital Management, L.P. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.